Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study | ||
| Egyptian Journal of Urology | ||
| Articles in Press, Accepted Manuscript, Available Online from 06 July 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/eju.2025.388743.1032 | ||
| Authors | ||
| Hossam Shaker1; assem abdalaziz1; Mahmoud Shoukry ElAdawy2; Rabie M Ibrahim3; Ahmed Yousef4; Ahmed Abdelatif4; samia heikal5; Mahmoud AbdElhamid6; Mohamed Mahmoud Dogha* 7; Ahmed Abdalgalil1; Hamada Ahmed Yousif8 | ||
| 1Department of Urology, Faculty of Medicine, Fayoum University, Egypt | ||
| 2fayoum university- faculty of medicine | ||
| 3urology , medicine, benisuif university | ||
| 4urology, medicine, benisuif university | ||
| 5Diagnostic Radiology Department, National Cancer Institute, Cairo University | ||
| 6Department of Urology, Faculty of Medicine, Cairo University, Egypt | ||
| 7keman fares | ||
| 8urology department, faculty of medicine, fayoum university | ||
| Abstract | ||
| Abstract: Objective: elicit influence of tadalafil and tamsulosin versus their combinations in treatment of LUTS in prostates < 40 ml. Materials and methods: A prospective randomized study conducted at Fayoum University Hospital from April 2023 to August 2024. A total of 95 participants > 45 years, with mild to intense LUTS, were enrolled. Participants were randomized into three groups: Tamsulosin group (0.4 mg per day), tadalafil group (5 mg per day), and combined group. International Prostate Symptom Score was the primary parameter. Secondary parameters were IIEF-5 items , maximum urinary flow rate, post-void residual urine, and quality of life. At baseline, these parameters were assessed, followed by evaluations at 1, 3, and 6 months. Results: IPSS score significanly increased in tamsulosin group relative to tadalafil group (p < 0.001) and in combination group relative to tadalafil group (p < 0.001). IIEF-5 scores also highly significantly enhanced in tadalafil group, with scores of 21.30±1.06 compared with 15.90±3.41 in tamsulosin group (p = 0.001) after treatment. Additionally, Q-max enhanced significantly in tamsulosin group, with an average of 13.07±1.29 ml/sec, whereas it was 11.73±0.90 ml/sec in tadalafil group (p = 0.001). Both PVR and IPSS QoL scores enhanced notably in tamsulosin and combination groups relative to those in tadalafil group. Importantly, no significant unfavorable events were reported in any group. Conclusion: patients with prostates <40 ml, tamsulosin and tadalafil are safe and efficient therapies for LUTS. When compared to tadalafil, tamsulosin considerably improved LUTS, and combined treatment produced better outcomes than tamsulosin alone. | ||
| Keywords | ||
| Tamsulosin; tadalafil; BPH and LUTS | ||
|
Statistics Article View: 131 |
||
